Originalarbeiten

2022

Barnert A-K, Hofmann P, Liekweg A, Kunze A, Scheid C, Hermes-Moll K, Osburg S,  Jaehde U.
Akzeptanz eines onkologischen Addendums zur Anwendung des Bundeseinheitlichen Medikationsplans in der oralen Tumortherapie. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen. 2022 [Online ahead of print.]

Weber L, Langebrake C, Picksak G, Schöning T, Schulze I, Jaehde U.
Medication errors in cancer therapy: Reports from German hospital pharmacies between 2008 and 2019. Oncol Pharm Pract. 2022 Nov 8:10781552221135130. [Online ahead of print.]

Ortland I, Mendel Ott M, Kowar M, Sippel C, Ko YD, Jacobs AH, Jaehde U.
Medication risks in older patients (70 +) with cancer and their association with therapy-related toxicity. BMC Geriatr. 2022 Aug 30;22(1):716.

Schmulenson E, Zimmermann N, Müller L, Kapsa S, Sihinevich I, Jaehde U.
Influence of the skeletal muscle index on pharmacokinetics and toxicity of fluorouracil. Cancer Med. 2022 Aug 8.

Haerdtlein A, Boehmer AM, Karsten Dafonte K, Rottenkolber M, Jaehde U, Dreischulte T. Prioritisation of Adverse Drug Events Leading to Hospital Admission and Occurring during Hospitalisation: A RAND Survey.
J Clin Med. 2022 Jul 22;11(15):4254.

Schmulenson E, Bovet C, Theurillat R, Decosterd LA, Largiadèr CR, Prost JC, Csajka C, Bärtschi D, Guckenberger M, von Moos R, Bastian S, Joerger M, Jaehde U.
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Br J Clin Pharmacol. 2022; 88( 12): 5336- 5347.

Schmitz K, Lenssen R, Rückbeil M, Berning D, Thomeczek C, Brokmann JC, Jaehde U, Eisert A.
The WHO High 5s project: medication reconciliation in a German university hospital. A prospective observational cohort study.
Z Evid Fortbild Qual Gesundhwes. 2022 Feb;168:27-32.

2021

Mc Laughlin AM, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland SL, Huitema ADR, Steeghs N, Müller L, Fuxius S, Illerhaus G, Joerger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, for the ON-TARGET Study Consortium.
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Cancers 2021; 13(24):6281.

Vucur C, Wirtz DA, Weinhold L, Zipfel M, Schmid M, Schmidt-Wolf IG, Jaehde U.
Drug-related problems in head and neck cancer patients identified by repeated medication reviews on consecutive therapy cycles.
J Oncol Pharm Pract. 2021 Sep;27(6):1439-1446.

2020

Schmulenson E, Krolop L, Simons S, RIngsdorf S, Ko YD, Jaehde U.
Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
Cancer Chemother Pharmacol 2020; 86: 435-444.

Barakat AK, Scholl C, Steffens M, Brandenburg K, Ising M, Lucae S, Holsboer F, Laje G, Kalayda GV, Jaehde U, Stingl JC. 
Citalopram-induced Pathways Regulation and Tentative Treatment-Outcome-Predicting Biomarkers in Lymphoblastoid Cell Lines From Depression Patients.
Transl Psychiatry 2020; 10: 210.

Waltering I, Scheppe S, Kurth V, Hempel G, Jaehde U.
Quality Indicators for Medication Reviews in Community Pharmacies.
Z Evid Fortbild Qual Gesundhwes 2020;  153: 44-53.

Möltgen S, Piumatti E, Massafra GM, Metzger S, Jaehde U, Kalayda GV.
Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity.
Cells 2020; 9: E1322.

Li X, Junge L, Taubert M, von Georg A, Dahlinger D, Starke C, Frechen S, Stelzer C, Kinzig M, Sörgel F, Jaehde U, Töx U, Goeser T, Fuhr U.
A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
J Clin Pharmacol 2020; 11:997-1005.

Arshad U, Ploylearmsaeng SA, Karlsson MO, Doroshyenko O, Langer D, Schömig E, Kunze S, Güner SA, Skripnichenko R, Ullah S, Jaehde U, Fuhr U, Jetter A, Taubert M. 
Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients.
Cancer Chemother Pharmacol 2020; 85: 711-722.

Ortland I, Mendel Ott M, Kowar M, Sippel C, Jaehde U, Jacobs AH, Ko YD. 
Comparing the performance of the CARG and the CRASH score for predicting toxicity in older patients in cancer.
J Geriatr Oncol 2020; 11:997-1005.

Dilruba S, Grondana A, Schiedel AC, Ueno NT, Bartholomeusz C, Cinatl J Jr, McLaughlin KM, Wass MN, Michaelis M, Kalayda GV.
Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin.
Cells 2020; 9: E515.

2019

Bitter K, Pehe C, Krüger M, Heuer G, Quinke R, Jaehde U. 
Pharmacist-led medication reviews for geriatric residents in German long-term care facilities. 
BMC Geriatr 2019; 19: 39.

2018

Schlender JF, Teutonico D, Coboeken K, Schnizler K, Eissing T, Willmann S, Jaehde U, Stass H.
A Physiologically- Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.
Clin Pharmacokinet 2018; 57: 1613-1634.

Lenssen R, Schmitz K, Griesel C, Heidenreich A, Schulz JB, Trautwein C, Marx N, Fitzner C, Jaehde U, Eisert A.
Comprehensive pharmaceutical care to prevent drug-related readmissions of dependent-living elderly patients: a randomized controlled trial.
BMC Geriatr 2018; 18: 135.

Kotz S, Kullmann M, Kalayda GV, Dyballa-Rukes N, Jaehde U, Metzger S.
Optimized two-dimensional gel electrophoresis in an alkaline pH range improves the identification of intracellular CFDA-cisplatin-protein adducts in ovarian cancer cells.
Electrophoresis. 2018; 39: 1488-1496.

Sarin N, Engel F, Rothweiler F, Cinatl J, Michaelis M, Frötschl R, Fröhlich H, Kalayda GV.
Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach 
Int J Mol Sci. 2018; 19: 767.

Buß I, Hamacher A, Sarin N, Kassack MU, Kalayda GV
Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
Metallomics 2018; 10: 414-425.

Stojković T, Rose O, Woltersdorf R, Marinković V, Manser T, Jaehde U.
Prospective systemic risk analysis of the dispensing process in German community pharmacies.
Int J Health Plann Manage 2018; 33: e320-e332.

2017

Schneider V, Chaib S, Spanier C, Knapp M, Moscvin V, Scordovillo L, Ewertz A, Jaehde U, Kalayda GV.
Transporter-Mediated Interaction Between Platinum Drugs and Sorafenib at the Cellular Level.
AAPS J. 2017; 20: 9.

Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, Jog S, Baburina I, Miller MC, Salamone SJ.
Validation of a commercial assay and decision support tool for routine paclitaxel therapeutic drug monitoring (TDM).
Ther Drug Monit. 2017; 39: 617-624.

Sarin N, Engel F, Kalayda GV, Mannewitz M, Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde U, Frötschl R
Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
PLoS One 2017; 12: e0181081.

Kalayda GV, Kullmann M, Galanski M, Gollos S. 
A fluorescent oxaliplatin derivative for investigation of oxaliplatin resistance using imaging techniques.
J Biol Inorg Chem 2017; 22:1259-1304.

Henrich A, Joerger M, Kraff S, Jaehde U, Huisinga W, Kloft C, Parra-Guillen ZP.
Semi-mechanistic bone marrow exhaustion pharmacokinetic/pharmacodynamic model for chemotherapy-induced cumulative neutropenia.
J Pharmacol Exp Ther. 2017; 362: 347-358.

Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U.
Population modelling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics and clinical outcome in sunitinib-treated cancer patients.
CPT Pharmacometrics Syst Pharmacol 2017; 6: 604-613.

Rose O, Jaehde U, Köberlein-Neu J.
Discrepancies between home medication and patient documentation in primary care.
Res Social Adm Pharm 2017; 14: 340-346.

van der Zanden LF, Vermeulen SH, Oskarsdottir A, Maurits JS, Diekstra MH, Ambert V, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia Donas J, Guarch Troyas R, Guchelaar HJ, Hartmann A, Hulsbergen-van de Kaa C, Jaehde U, Junker K, Martinez-Cardus A, Masson G, Oosterwijk-Wakka J, Radu MT, Rafnar T, Rodriguez-Antona C, Roessler M, Ruijtenbeek R, Stefansson K, Warren A, Wessels L, Eisen T, Kiemeney LA, Oosterwijk E.
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
Urol Oncol 2017; 35: 529.e9-529.e16

Hendrayana T, Wilmer A, Kurth V, Schmidt-Wolf IG, Jaehde U. 
Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application.
Sci Pharm 2017; 85: 8

Kaestner B, Spicher K, Jaehde U, Enzmann H.
Effects of sorafenib and cisplatin on preneoplastic foci of altered hepatocytes in fetal turkey liver.
Toxicol Res 2017; 6: 54-62

Stojković T, Marinović V, Jaehde U, Manser T.
Using Failure Mode and Effects Analysis to Reduce Patient Safety Riscs Related to the Dispensing Process in the Community Pharmacy Setting.
Res Social Adm Pharm 2017; 13: 1159-1166

2016

Köberlein-Neu J, Mennemann H, Hamacher S, Waltering I, Jaehde U, Schaffert C, Rose O.
Interprofessional Medication Management in Patients with Multiple Morbidities.
Dtsch Arztebl Int 2016; 113: 741-748

Hagelstein V, Ortland I, Wilmer A, Mitchell SA, Jaehde U.
Validation of the German patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE).
Ann Oncol 2016; 27: 2294-2299

Sarin N, Engel F, Kalayda GV, Frötschl R, Cinatl J Jr, Rothweiler F, Michaelis M, Fröhlich H, Jaehde U.
Knowledge-based approach to identify key determinants of cisplatin sensitivity.
Int J Clin Pharmacol Ther 2016; 55: 686-689

Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U.
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Ann Oncol 2016 Oct; 27:1895-1902

Atzler D, Schönhoff M, Cordts K, Ortland I, Hoppe J, Hummel FC, Gerloff C, Jaehde U, Jagodzinski A, Böger RH, Choe CU, Schwedhelm E.
Oral supplementation with L-homoarginine in young volunteers.
Br J Clin Pharmacol 2016; 82: 1477-1485

Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U.
Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals.
Clin Pharmacokinet 2016; 55: 1573-1589

Rose O, Mennemann H, John C, Lautenschläger M, Mertens-Keller D, Richling K, Waltering I, Hamacher S, Felsch M, Herich L, Czarnecki K, Schaffert C, Jaehde U, Köberlein-Neu J.
Priority Setting and Influential Factors on Acceptance of Pharmaceutical Recommendations in Collaborative Medication Reviews in an Ambulatory Care Setting - Analysis of a Cluster Randomized Controlled Trial (WestGem-Study).
PLoS One 2016; 11: e0156304

Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T, Kunzmann V, Stoetzer OJ, Suttmann I, Braess J, Birkmann J, Roessler M, Moritz B, Kraff S, Salamone SJ, Jaehde U.
Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
Clin Colorectal Cancer 2016; 15: 381-388

Lenssen R, Heidenreich A, Schulz JB, Trautwein C, Fitzner C, Jaehde U, Eisert A.
Analysis of drug-related problems in three departments of a German University hospital.
Int J Clin Pharm 2016; 38: 119-126

2015

Vossen MG, Wenisch JM, Maier-Salamon A, Fritsch A, Saria K, Zuba C, Jilch S, Lemmerer R, Unger M, Jaehde U, Jäger W, Thalhammer F.
Doripenem treatment during continuous renal replacement therapy.
Antimicrob Agents Chemother 2015; 60: 1687-1694

Dilruba S, Michaelis M, Cinatl J, Kalayda GV. 
Relevance of subcellular localization of extracellular signal-regulated kinase 1/2 (ERK1/2) for cisplatin resistance. 
Int J Clin Pharmacol Ther 2015; 53(12):1041-1045.

Kullmann M, Kotz S, Hellwig M, Kalayda GV, Metzger S, Jaehde U.
GRP78 knockdown does not affect cytotoxicity of cisplatin in ovarian cancer cells.
Int J Clin Pharmacol Ther 2015; 53: 1038-1040

Kullmann M, Kalayda GV, Hellwig M, Kotz S, Hilger RA, Metzger S, Jaehde U.
Assessing the contribution of the two protein disulfide isomerases PDIA1 and PDIA3 to cisplatin resistance.
J Inorg Biochem 2015; 153: 247-252

Suleiman AA, Frechen S, Scheffler M, Zander T, Nogova L, Kocher M, Jaehde U, Wolf J, Fuhr U.
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
AAPS J 2015; 17: 1483-1491

Kotz S, Kullmann M, Crone B, Kalayda GV, Jaehde U, Metzger S.
Combination of two-dimensional gel electrophoresis and a fluorescent carboxyfluorescein diacetate labeled cisplatin analogue allows the identification of intracellular cisplatin-protein adducts
Electrophoresis 2015; 36: 2811-2819

Kraff S, Lindauer A, Joerger M, Salamone SJ, Jaehde U.
Excel®-Based Tool for Pharmacokinetically-Guided Dose Adjustment of Paclitaxel.
Ther Drug Monit. 2015; 37: 725-732

Kraff S, Nieuweboer AJ, Mathijssen RH, Baty F, de Graan AJ, van Schaik RH, Jaehde U, Joerger M.
Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy.
Cancer Chemother Pharmacol 2015; 75: 975-983

Retlich S, Duval V, Graefe-Mody U, Friedrich C, Patel S, Jaehde U, Staab A.
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.
Clin Pharmacokinet 2015; 54: 737-750

Zabel R, Kullmann M, Kalayda GV, Jaehde U, Weber G.
Optimized sample preparation strategy for the analysis of low-molecular-mass adducts of a fluorescent cisplatin analogue in cancer cell lines by CE-Dual-LIF.
Electrophoresis 2015; 36: 509-517

Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, Ruehs H, Keyver-Paik MD, Rudlowski C, Weber S, Kiefer N, Poelcher ML, Thiesler T, Rostamzadeh B, Mallmann M, Schaefer N, Permantier M, Latten S, Kalff J, Thomale J, Jaehde U, Kuhn WC.
HIPEC ROC I: A phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Int J Cancer 2015; 136: 699-708

2014

Mross K, Scheulen M, Strumberg D, Kuhlmann J, Kanefendt F, Sörgel F, Jaehde U, Burkholder I, Moritz B, Büchert M.
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases - a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
Int J Clin Pharmacol Ther 2014; 52: 642-652

2013

Mohn C, Häcker HG, Hilger RA, Gütschow M, Jaehde U.
Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin.
Pharmazie 2013; 68: 622-627

Krolop L, Ko Y-D, Schwindt PF, Schumacher C, Fimmers R, Jaehde U.
Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study.
BMJ Open 2013; 3: e003139

Koch M, Krieger ML, Stölting D, Brenner N, Beier M, Jaehde U, Wiese M, Royer HD, Bendas G.
Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling.
Biochem Pharmacol 2013; 85: 1077-1090

Schneider V, Krieger ML, Bendas G, Jaehde U, Kalayda GV.
Contribution of intracelluar ATP to cisplatin resistance of tumor cells.
J Biol Inorg Chem 2013; 18: 165-174

2012

Kalayda GV, Wagner CH, Jaehde U.
Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells.
J Inorg Biochem 2012; 116: 1-10

Rühs H, Becker A, Drescher A, Panetta JC, Pui C-H, Relling MV, Jaehde U.
Population PK/PD Model of Homocysteine Concentrations after High-Dose Methotrexate Treatment in Patients with Acute Lymphoblastic Leukemia.
PLoS One 2012; 7: e46015

Kanefendt F, Lindauer A, Mross L, Fuhr U, Jaehde U.
Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.
J Pharm Biomed Anal 2012; 70: 485-491

Joerger M, Kraff S, Huitema AD, Feiss G, Moritz B, Schellens JH, Beijnen JH, Jaehde U.
Evaluation of a Pharmacology-Driven Dosing Algorithm of 3-Weekly Paclitaxel Using Therapeutic Drug Monitoring: A Pharmacokinetic-Pharmacodynamic Simulation Study.
Clin Pharmacokinet 2012; 51: 607-617

Buss I, Kalayda GV, Lindauer A, Reithofer MR, Galanski M, Keppler BK, Jaehde U.
Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues.
J Biol Inorg Chem 2012; 17: 699–708

Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, Jaehde U.
Pharmaceutical care for patients with breast and ovarian cancer.
Support Care Cancer 2012; 20: 2669-2677

Besançon OG, Tytgat GA, Meinsma R, Leen R, Hoebink J, Kalayda GV, Jaehde U, Caron HN, van Kuilenburg AB.
Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids.
Cancer Lett 2012; 319(1):23-30.

2011

Simons S, Ringsdorf S, Braun M, Mey UJ, Schwindt PF, Ko YD, Schmidt-Wolf I, Kuhn W, Jaehde U.
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Support Care Cancer 2011; 19: 1009-1018

Döhler N, Krolop L, Ringsdorf S, Meier K, Ko YD, Kuhn W, Schwalbe O, Jaehde U.
Task allocation in cancer medication management - integrating the pharmacist.
Patient Educ Couns 2011; 83: 367-374

Buss I, Garmann D, Galanski M, Weber G, Kalayda GV, Keppler BK, Jaehde U.
Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?
J Inorg Biochem 2011; 105: 709-717

2010

Retlich S, Duval V, Ring A, Staab A, Hüttner S, Jungnik A, Jaehde U, Dugi KA, Graefe-Mody U.
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Clin Pharmacokinet 2010; 49: 829-840

Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U.
Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.
Clin Pharmacol Ther 2010; 88: 643-651

Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A
Impact of target-mediated drug disposition on Linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients.
J Clin Pharmacol 2010; 50: 873-85

Lindauer A, Di Gion P, Kanefendt F, Tomalik-Scharte D, Kinzig M, Rodamer M, Dodos F, Sörgel F, Fuhr U, Jaehde U.
Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.
Clin Pharmacol Ther 2010; 87: 601-608

Lindauer A, Eickhoff C, Kloft C, Jaehde U.
Population pharmacokinetics of high-dose carboplatin in children and adults.
Ther Drug Monit 2010; 32: 159-168

Krieger ML, Eckstein N, Schneider V, Koch M, Royer HD, Jaehde U, Bendas G.
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
Int J Pharm 2010; 389: 10-17

Rotte A, Garmann D, Buss I, Jaehde U.
Effect of extracellular ATP on cisplatin-induced cytotoxicity in human ovarian carcinoma cells.
Chemotherapy 2010; 56: 1-8

Swennen EL, Ummels V, Buss I, Jaehde U, Bast A, Dagnelie PC.
ATP sensitizes H460 lung carcinoma cells to cisplatin-induced apoptosis.
Chem Biol Interact 2010; 184: 338-345

Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Jaehde U, Reiter A, Naber KG, Rodamer M, Sörgel F.
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.
Br J Clin Pharmacol 2010; 69: 167-178